Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

Share Price is delayed by 15 minutes
Get Live Data
3179.00    95.00 (3.08%)
Bid:
3186.00
Ask:
3188.00
Spread: 2.00 (0.063%)
Market Cap: £4.43b
CRDA Live PriceLast checked at - London Stock Exchange

Intraday Croda International Share Chart

First Quarter Trading Statement

28 Apr 2011 07:00

RNS Number : 5748F
Croda International PLC
28 April 2011
 



28 April 2011

 

 

Croda International Plc

First quarter trading statement

 

Martin Flower, Chairman of Croda International Plc, is due to provide the following update on first quarter trading for the period ended 31 March 2011 at today's Annual General Meeting:

 

"I am pleased to report a strong start to 2011 with record sales and profits in both Consumer Care and Industrial Specialities with robust demand continuing across all major geographies.

 

Group sales increased 13.2% to £277.9m (2010: £245.5m) despite adverse currency translation of 2.4%. Overall volumes were slightly down as we continue to reposition our Industrial Specialities operations away from lower price/higher volume products towards more speciality business. Average prices rose during the quarter as we passed on significant raw material cost increases into the market. We have implemented further price increases where necessary in April.

 

Group pre-tax profit from continuing operations increased 40.2% to £60.7m (2010: £43.3m).

 

On a segmental basis, Consumer Care operating profit was up 22.2% to £42.4m (2010: £34.7m) with Personal Care, Health Care and Crop Care all seeing significant sales and profit growth.

 

Industrial Specialities again achieved extremely robust profit growth of 63.7% to £18.5m (2010: £11.3m) despite the volume decline described above and adverse currency movements.

 

Net debt reduced by £5.3m since the year-end to £215.1m despite an unfavourable currency movement of £1.5m.

 

We are pleased with the performance to date and are confident of reporting further progress throughout 2011."

 

 

 

 

For further information, please contact:

 

Mike Humphrey, Group Chief Executive

Tel: 01405 860551

Sean Christie, Group Finance Director

Hazel Stevenson, Financial Dynamics

Tel: 0207 269 7176

 

 

The company will host a conference call for analysts at 8.00am (BST) today:

Dial-In: +44 (0)1452 542 304

Please quote "Croda International"to gain access to the call

 

 

Croda International Plc

Unaudited income statement before tax and exceptional items

31 March 2011

£m

3 months to

3 months to

31 March

31 March

2011

2010

Change

Consumer Care

146.3

128.1

+14.2%

Industrial Specialities

131.6

117.4

+12.1%

Revenues from continuing operations

277.9

245.5

+13.2%

Consumer Care

42.4

34.7

+22.2%

Industrial Specialities

18.5

11.3

+63.7%

Operating profit from continuing operations

60.9

46.0

+32.4%

Net bank and loan interest payable

(2.0)

(2.8)

Net retirement benefit scheme financing

1.8

0.1

Profit before tax from continuing operations

60.7

43.3

+40.2%

Operating margin

21.9%

18.7%

Analysis of turnover uplift for continuing operations

Volume

-0.5%

Currency impact

-2.4%

Price/mix

+16.1%

+13.2%

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTIRMATMBJTBJB
Date   Source Headline
26th Apr 20198:21 amRNSTotal Voting Rights
25th Apr 201910:25 amRNSDirectorate Change
25th Apr 20199:53 amRNSResult of AGM
12th Apr 20194:28 pmRNSDirector/PDMR Shareholding
8th Apr 20194:45 pmRNSDirector/PDMR Shareholding
4th Apr 20199:32 amRNSDirector/PDMR Shareholding
2nd Apr 20199:04 amRNSDirector/PDMR Shareholding
28th Mar 201911:13 amRNSDirector/PDMR Shareholding
26th Mar 20198:16 amRNSDirector/PDMR Shareholding
18th Mar 20195:26 pmRNSAnnual Financial Report
13th Mar 20191:42 pmRNSDirector/PDMR Shareholding
12th Mar 20192:22 pmRNSDirector/PDMR Shareholding
12th Mar 20192:21 pmRNSDirector/PDMR Shareholding
11th Mar 20192:16 pmRNSDirector/PDMR Shareholding
6th Mar 20193:53 pmRNSTransaction in Own Shares
6th Mar 201910:07 amRNSDirector/PDMR Shareholding
6th Mar 201910:07 amRNSDirector/PDMR Shareholding
6th Mar 201910:06 amRNSDirector/PDMR Shareholding
6th Mar 201910:03 amRNSDirector/PDMR Shareholding
6th Mar 201910:02 amRNSDirector/PDMR Shareholding
6th Mar 201910:01 amRNSDirector/PDMR Shareholding
6th Mar 201910:01 amRNSDirector/PDMR Shareholding
6th Mar 201910:00 amRNSDirector/PDMR Shareholding
6th Mar 20199:58 amRNSDirector/PDMR Shareholding
6th Mar 20199:57 amRNSDirector/PDMR Shareholding
26th Feb 20197:00 amRNSResults for the year ended 31 December 2018
12th Feb 20194:47 pmRNSDirector/PDMR Shareholding
11th Jan 20194:21 pmRNSDirector/PDMR Shareholding
31st Dec 20187:00 amRNSAcquisition completion
17th Dec 20187:00 amRNSAcquisition of global vaccine adjuvant specialist
12th Dec 20181:14 pmRNSDirector/PDMR Shareholding
22nd Nov 20181:54 pmRNSDirector Declaration
22nd Nov 20188:07 amRNSDirector/PDMR Shareholding
14th Nov 20182:48 pmRNSDirector/PDMR Shareholding
14th Nov 20188:24 amRNSDirector/PDMR Shareholding
1st Nov 20187:00 amRNSTrading Update for the Third Quarter 2018
26th Oct 20187:00 amRNSAcquisition update
12th Oct 20181:42 pmRNSDirector/PDMR Shareholding
4th Oct 20183:03 pmRNSDirector/PDMR Shareholding
4th Oct 20183:01 pmRNSDirector/PDMR Shareholding
28th Sep 20183:35 pmRNSDirector/PDMR Shareholding
11th Sep 20184:50 pmRNSDirector/PDMR Shareholding
6th Sep 20184:07 pmRNSDirector/PDMR Shareholding
5th Sep 20187:00 amRNSAppointment of Broker
22nd Aug 201811:06 amRNSDirector Declaration
13th Aug 20184:37 pmRNSDirector/PDMR Shareholding
7th Aug 20189:11 amRNSDirector/PDMR Shareholding
31st Jul 20184:16 pmRNSDirector/PDMR Shareholding
25th Jul 20184:19 pmRNSDirector/PDMR Shareholding
25th Jul 20187:00 amRNSResults for the six months ended 30 June 2018

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.